ProACT™ for Male Stress Urinary Incontinence – A possible Alternative Outside The United States
Starvation – A New Treatment for Advanced Prostate Cancer
What is the role of diet in the treatment of prostate cancer? We hear about changing our diet as a way to slow down prostate cancer progression and we hear about diet as a preventive measure against prostate cancer. It is possible that there could be a new twist on this story, in the future, [...]
Using the Complete Team to Battle Advanced Prostate Cancer
It is important to learn to use as many resources as possible as we take our trip through the treatment processes for advanced prostate cancer. Many of us limit ourselves to just our doctor and perhaps their office nurse or Physician Assistant. The reality is that there are many other individuals who can make out [...]
Early Zytiga & Prednisone Trial For Metastatic Castration Resistant Prostate Cancer Is Un-blinded
In one of those situations when actual clinical practice precedes the normal drug development process a recent announcement from Janssen Research & Development, LLC (Johnson & Johnson) informs that they have un-blinded their Phase 3 study, COU-AA-302, which clearly demonstrates that Zytiga (abiraterone acetate), when taken with prednisone, is effective in treating both mildly symptomatic [...]
Denosumab (Xgeva) Benefits Greatest in Men with Rapid PSA Kinetics
Denosumab (Xgeva), the recently approved and only therapy that prolongs bone metastasis-free survival in men with non-metastatic castrate-resistant prostate cancer (CRPC) who are at high risk for the spread of prostate cancer metastasis to bone seems to work best in men with very rapid prostate specific antigen (PSA) kinetics. The large 1,432 man, placebo controlled, [...]
More From ASCO – Too Many Patients with Advanced Prostate Cancer Do Not Get Required Treatment
Abstract No:101 at the recent ASCO Conference It is sad, but it is true, a subset of men presenting with advanced prostate cancer never receive proper therapy. This can be attributed to a variety of factors including poor functional status, co-morbidities, and patient preference. The researchers sought to determine the prevalence, and characteristics, of this [...]
Will the FDA Approve Xgeva – It is “Up In The Air”
Prior to the formal review, the FDA has raised questions about the ultimate approval of Amgen’s Xgeva (denosumab) for men with metastatic, advanced prostate cancer who have not yet developed metastasized to the bone. Xgeva has been shown to delay tumors spreading to bones, but it does not extend life, the holy grail of the [...]
Video Interview Explaining That Provenge Actually Has A 7.8 Month Life Extension Advantage
As a follow up to my last post about the three posters that appeared at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium meeting I am going to share with you a video interview with Dr. Chadi Nabhan. Dr. Nabhan talks about his presentation about the phase III results of the Provenge IMPACT [...]
REVLIMID FAILS TO EXTEND SURVIVAL IN ADVANCED PROSTATE CANCER
The late-stage trial of Revlimid (lenalidomide) for the treatment of advanced prostate cancer has been discontinued after preliminary data shows that it does not extend survival! The independent monitoring committee recommended that the pivotal Phase III Mainsail trial be halted after it determined that adding Revlimid to standard treatments would not significantly increase the overall [...]
The Value of Evaluating Circulating Tumor Cells – Better Survival Predictions
The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]